You are here

FDA Approves Generic Version of Flexeril

PITTSBURGH, Feb. 6 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE:MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Cyclobenzaprine Hydrochloride Tablets USP, 5 mg. Cyclobenzaprine Tablets are the AB-rated generic equivalent of McNeil's Flexeril(R) Tablets. U.S. sales for the 5 mg strength of Flexeril(R) were approximately $93 million for the 12-month period ending June 30, 2005, according to IMS Health.

This product will begin shipping immediately.

Source: Mylan Laboratories, Inc.

Recent Headlines

Company says it is offering a more affordable generic to the agent used to treat varicose veins
Company, FDA held a meeting to discuss trials in bunion, "tummy tuck" patients
New model uses piezoelectric material used in microphones and high-end speakers
Rozanolixizumab touted as possible alternative to standard therapy of corticosteroids, intravenous immunoglobulin
18 of 25 were 'iron replete' after a single infusion
Intrauterine environment may have a 'programming effect' on fetal heart
Heart rate variability may pinpoint who will benefit